The company also commented that the database for the North American phase III clinical trial for Alzhemed has been locked, which means that Neurochem has finished collecting data for the trial.
The analysis in the study is ongoing and entails employing an accurate statistical model that appropriately describes the data and provides accurate results.
Neurochem has been advised by its external team of statisticians that adjustment to the initial statistical model, as set out in the statistical plan, would be necessary to provide accurate results. Neurochem is still expecting its results on time despite being informed that it could take several weeks, perhaps longer, before the results are known.